<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3954">
  <stage>Registered</stage>
  <submitdate>27/05/2013</submitdate>
  <approvaldate>27/05/2013</approvaldate>
  <nctid>NCT01865240</nctid>
  <trial_identification>
    <studytitle>Renal Denervation for Resistant Hypertension</studytitle>
    <scientifictitle>Renal Denervation for Resistant Hypertension</scientifictitle>
    <utrn />
    <trialacronym>RDNP-2012-01</trialacronym>
    <secondaryid>NHMRC</secondaryid>
    <secondaryid>008/12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Renal Denervation

Experimental: Renal Denervation Group - participants randomised to undergo the renal denervation procedure

No Intervention: Usual care - participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets


Treatment: devices: Renal Denervation
Renal Denervation Catheter

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>blood pressure control - percentage of patients to achieve Blood Pressure (BP) target (BP &lt;140/90mmHg, or &lt;130/80mmHg in diabetic patients) at 6 months post procedure</outcome>
      <timepoint>6 months post procedure</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>number of drugs required to reach blood pressure target - number of drugs required to reach blood pressure target</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>time to achieve blood pressure target - time to achieve blood pressure target</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of sympathetic nerve activity - Changes in Muscle Sympathetic Nerve Activity (MSNA), renal and whole body Norepinephrine (NE) spillover</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Left Ventricular Structure and Function - Change in Left Ventricular mass index, ejection fraction, diastolic filling as assessed by echocardiogram</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Quality of Life - Change in Quality of Life as assessed by relevant questionnaires</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum and Urine Biochemistry - Plasma renin activity, aldosterone, estimated Glomerular Filtration Rate (eGFR), urine albumin-to-creatinine ratio (UACR), inflammatory markers, 24hour urinary creatinine clearance, sodium, fasting glucose, fasting insulin, c-peptide, Homeostasis Model Assessment (HOMA) index, lipid profile</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in markers of arterial stiffness - Change in markers of arterial stiffness including Augmentation Index (AI) and Pulse Wave Velocity (PWV)</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  systolic BP =140mmHg or =130mmHg for patients with diabetes

          -  concurrent treatment with =3 anti-hypertensive drugs</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  renal artery anatomy ineligible for treatment

          -  eGFR &lt;15mL/min/1.73m2 (using Modification of Diet in Renal Disease (MDRD) calculation)

          -  female participants of childbearing potential must have negative pregnancy test prior
             to treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>5</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Baker IDI Heart &amp; Diabetes Inst - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Baker IDI Heart and Diabetes Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study investigating the effectiveness of renal denervation in lowering blood
      pressure in people whose blood pressure is not adequately controlled despite treatment with 3
      or more blood pressure lowering drugs. The study is designed to compare the effects of renal
      denervation to a usual care group receiving additional blood pressure lowering drugs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01865240</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Markus Schlaich, MD</name>
      <address>Baker IDI Heart &amp; Diabetes Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>